Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Source : https://pubmed.ncbi.nlm.nih.gov/38484122/
Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered...
Many RET-selective inhibitors, characterized by heightened specificity and potency, have been developed, representing a substantial breakthrough in the field of RET precision oncology.
Multicenter Evaluation of an Automated, Multiplex, RNA-Based Molecular Assay for Detection of ALK, ROS1, RET Fusions and MET Exon 14 Skipping in NSCLC
Source : https://pubmed.ncbi.nlm.nih.gov/38492039/
The current study assessed the performance of the fully automated RT-PCR-based Idylla™ GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK, ROS1, RET, and MET...
Expression-imbalance-based detection of potentially novel fusions may be easily verified with other routine technologies without delaying treatment initiation.
Aberrant SOX10 and RET Expressions in Patients With Hirschsprung Disease
Source : https://pubmed.ncbi.nlm.nih.gov/38493096
Our study shows aberrant SOX10 and RET expressions in HSCR patients, implying the critical role of SOX10 and RET in the pathogenesis of HSCR, particularly in the Indonesian population. Our...
RET expressions were significantly downregulated in both ganglionic (11.71-fold) and aganglionic (29.96-fold) colon of study patients with Hirschsprung disease versus controls.
Targeting RET Alterations in Non-Small Cell Lung Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38494387/
Rearranged during transfection (RET) alterations, which lead to aberrant activation of the RET proto-oncogene, have been identified in various cancers. In non-small cell lung cancer (NSCLC), RET mutations often manifest...
This review provides an overview of the biology of RET in NSCLC, methods of RET testing, and a comprehensive analysis of the clinical outcomes associated with multikinase and selective RET inhibitors for NSCLC.
RET Fusion Testing in Patients With NSCLC: the RETING Study
Source : https://pubmed.ncbi.nlm.nih.gov/38525319/
In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective...
Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively).